Understand the source comparison
Comparison: Peptides vs Standard Tennis Elbow Treatments
BPC-157 Peptide Upregulates VEGF and collagen synthesis; enhances fibroblast migration 4–8 weeks for peak benefit Increases Type I collagen density by 40–60% (animal data) Lower. Strengthens tendon structure Evidence strongest in animal models; human data limi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 Peptide
- Upregulates VEGF and collagen synthesis; enhances fibroblast migration
- 4–8 weeks for peak benefit
- Increases Type I collagen density by 40–60% (animal data)
- Lower. Strengthens tendon structure
- Evidence strongest in animal models; human data limited to case series but mechanistically sound
- TB-500 Peptide
- Binds actin to improve cell migration; shifts macrophage polarisation to M2 phenotype
- 4–8 weeks for structural repair
- Reduces fibrosis; preserves normal collagen architecture
- Lower. Improves tensile strength
- Equine data robust; human clinical trials absent but veterinary outcomes translate well
- Corticosteroid Injection
- Suppresses COX-2 and inflammatory cytokines
- 1–2 weeks for pain relief
- Degrades collagen cross-linking long-term
- 63% higher at 12 months (systematic review data)
- Short-term symptom relief at cost of structural integrity. Avoid if possible
- NSAIDs (oral)
- Blocks COX enzymes to reduce prostaglandin synthesis
- Days to weeks for pain control
- Inhibits inflammatory resolution phase required for repair
- Moderate. Delays healing if used long-term
- Symptom management only; does not address underlying tendon pathology
- Physical Therapy
- Eccentric loading to stimulate collagen remodelling
- 6–12 weeks minimum
- Improves collagen alignment through mechanical load
- Low if load progression is gradual
- Gold standard conservative treatment; peptides may accelerate this timeline
- Platelet-Rich Plasma (PRP)
- Growth factors from autologous platelets stimulate repair
- 8–12 weeks for noticeable effect
- Variable. Depends on platelet concentration and preparation method
- Moderate. Quality inconsistent across providers
- Evidence mixed; preparation protocols not standardised